Skip to Main Content
Newsroom
Get in Touch
LinkedIn
Editas Medicine Linkedin
Research and Pipeline
CRISPR Gene Editing
For Patients
Who We Are
Join Our Team
Investors
Newsroom
Get in Touch
LinkedIn
Purchasing Policy Terms and Conditions
+
-
Editas Newsroom
Aug
30
Editas Medicine Announces Upcoming Investor Events
Aug
2
Editas Medicine Announces Second Quarter 2023 Results and Business Updates
Jul
27
Editas Medicine and Azzur Group Expand Partnership to Accelerate Editas’ Manufacturing Capabilities for Advancing the EDIT-301 Program Through Approval to Commercialization